S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
Log in

SUMMIT THERAPEU/S Stock Price, Forecast & Analysis (NASDAQ:SMMT)

$1.56
+0.07 (+4.70 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$1.54
Now: $1.56
$1.68
50-Day Range
$1.36
MA: $1.66
$1.83
52-Week Range
$1.10
Now: $1.56
$2.46
Volume29,400 shs
Average Volume45,548 shs
Market Capitalization$50.08 million
P/E Ratio1.86
Dividend YieldN/A
Beta1.23
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SMMT
CUSIPN/A
Phone44-12-3544-3939

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$56.50 million
Cash Flow$1.05 per share
Book Value$4.08 per share

Profitability

Net Income$9.99 million
Net Margins-1,432.73%

Miscellaneous

Employees61
Market Cap$50.08 million
Next Earnings Date12/10/2019 (Estimated)
OptionableOptionable

Receive SMMT News and Ratings via Email

Sign-up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.


SUMMIT THERAPEU/S (NASDAQ:SMMT) Frequently Asked Questions

What is SUMMIT THERAPEU/S's stock symbol?

SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT."

How were SUMMIT THERAPEU/S's earnings last quarter?

SUMMIT THERAPEU/S (NASDAQ:SMMT) announced its quarterly earnings results on Friday, October, 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.08. The firm had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.43 million. SUMMIT THERAPEU/S had a negative net margin of 1,432.73% and a negative return on equity of 61.73%. View SUMMIT THERAPEU/S's Earnings History.

When is SUMMIT THERAPEU/S's next earnings date?

SUMMIT THERAPEU/S is scheduled to release their next quarterly earnings announcement on Tuesday, December 10th 2019. View Earnings Estimates for SUMMIT THERAPEU/S.

What price target have analysts set for SMMT?

2 brokers have issued 12-month price objectives for SUMMIT THERAPEU/S's stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate SUMMIT THERAPEU/S's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 28.2% from the stock's current price. View Analyst Price Targets for SUMMIT THERAPEU/S.

What is the consensus analysts' recommendation for SUMMIT THERAPEU/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SUMMIT THERAPEU/S in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SUMMIT THERAPEU/S.

Has SUMMIT THERAPEU/S been receiving favorable news coverage?

News stories about SMMT stock have trended positive this week, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. SUMMIT THERAPEU/S earned a news sentiment score of 2.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for SUMMIT THERAPEU/S.

Who are some of SUMMIT THERAPEU/S's key competitors?

What other stocks do shareholders of SUMMIT THERAPEU/S own?

Who are SUMMIT THERAPEU/S's key executives?

SUMMIT THERAPEU/S's management team includes the folowing people:
  • Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)
  • Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)
  • Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)
  • Ms. Melissa Strange FCCA, VP of Fin. & Company Sec. (Age 39)
  • Ms. Michelle Avery, Director of Investor Relations

When did SUMMIT THERAPEU/S IPO?

(SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

How do I buy shares of SUMMIT THERAPEU/S?

Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is SUMMIT THERAPEU/S's stock price today?

One share of SMMT stock can currently be purchased for approximately $1.56.

How big of a company is SUMMIT THERAPEU/S?

SUMMIT THERAPEU/S has a market capitalization of $50.08 million and generates $56.50 million in revenue each year. The company earns $9.99 million in net income (profit) each year or $0.84 on an earnings per share basis. SUMMIT THERAPEU/S employs 61 workers across the globe.View Additional Information About SUMMIT THERAPEU/S.

What is SUMMIT THERAPEU/S's official website?

The official website for SUMMIT THERAPEU/S is http://www.summitplc.com/.

How can I contact SUMMIT THERAPEU/S?

SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected]


MarketBeat Community Rating for SUMMIT THERAPEU/S (NASDAQ SMMT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  509
MarketBeat's community ratings are surveys of what our community members think about SUMMIT THERAPEU/S and other stocks. Vote "Outperform" if you believe SMMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Featured Article: Buy Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel